Pradeep Rajkumar1, Binu Susan Mathew2, Saikat Das3, Rajesh Isaiah3, Subashini John4, Ratna Prabha5, Denise Helen Fleming6. 1. Fellow, Clinical Pharmacology Unit, Department of Pharmacology and Clinical Pharmacology, Christian Medical College Hospital , Vellore, India . 2. Professor, Clinical Pharmacology Unit, Department of Pharmacology and Clinical Pharmacology, Christian Medical College Hospital , Vellore, India . 3. Associate Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India . 4. Professor, Department of Radiation Oncology, Christian Medical College Hospital , Vellore, India . 5. Assistant Professor, Clinical Pharmacology Unit, Christian Medical College Hospital , Vellore, India . 6. Professor, Clinical Pharmacology Unit, Christian Medical College Hospital , Vellore, India .
Abstract
INTRODUCTION: Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear. AIM: The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy. MATERIALS AND METHODS: Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method. RESULTS: The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly. CONCLUSION: We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.
INTRODUCTION:Cisplatin has radiosensitizing properties and the best sensitization to radiotherapy occurs with a higher plasma concentration of cisplatin. To our knowledge the optimal time sequence between chemotherapy and administration of radiation therapy, to obtain maximum effect from concurrent chemoradiation is unclear. AIM: The aim of this study was to measure the two cisplatin infusion regimens in order to determine the total and free cisplatin post infusion concentration changes over time. These changes may have clinical implications on the optimum time of administration of post infusion radiation therapy. MATERIALS AND METHODS: Two cohorts of patients were recruited and both, total and free plasma concentration of cisplatin following long and short durations of intravenous infusion was determined. Blood samples were collected at 0.5, 1, 1.5, 2, 3 and 5 hours from the start of the infusion in the 1hour infusion group and at 2, 3, 3.5, 4, 6 and 24 hours from the start of the infusion, in the 3 hour infusion group. Total and free cisplatin concentrations were measured using a validated HPLC-UV method. RESULTS: The highest concentration of total and free cisplatin was achieved at the end of the infusion in both regimens. Total cisplatin concentration declined 30 minutes after the end of infusion in both the groups. After 1hour of discontinuing cisplatin, the free cisplatin concentration also declined significantly. CONCLUSION: We conclude that radiation should be administered within 30 minutes of completion of the infusion irrespective of the duration of infusion.
Authors: K Ikeda; M Terashima; H Kawamura; I Takiyama; K Koeda; A Takagane; N Sato; K Ishida; T Iwaya; C Maesawa; H Yoshinari; K Saito Journal: Jpn J Clin Oncol Date: 1998-03 Impact factor: 3.019
Authors: Xun Ming; Arnold Groehler; Erin D Michaelson-Richie; Peter W Villalta; Colin Campbell; Natalia Y Tretyakova Journal: Chem Res Toxicol Date: 2017-03-29 Impact factor: 3.739
Authors: Anna Herland; Ben M Maoz; Debarun Das; Mahadevabharath R Somayaji; Rachelle Prantil-Baun; Richard Novak; Michael Cronce; Tessa Huffstater; Sauveur S F Jeanty; Miles Ingram; Angeliki Chalkiadaki; David Benson Chou; Susan Marquez; Aaron Delahanty; Sasan Jalili-Firoozinezhad; Yuka Milton; Alexandra Sontheimer-Phelps; Ben Swenor; Oren Levy; Kevin K Parker; Andrzej Przekwas; Donald E Ingber Journal: Nat Biomed Eng Date: 2020-01-27 Impact factor: 25.671
Authors: Liang Song; Ewan M McNeil; Ann-Marie Ritchie; Katy R Astell; Charlie Gourley; David W Melton Journal: BMC Cancer Date: 2017-12-18 Impact factor: 4.430
Authors: Jaime N Wertman; Nicole Melong; Matthew R Stoyek; Olivia Piccolo; Stewart Langley; Benno Orr; Shelby L Steele; Babak Razaghi; Jason N Berman Journal: Elife Date: 2020-07-28 Impact factor: 8.140
Authors: Ratnakar Singh; Zeeshan Fazal; Andrea K Corbet; Emmanuel Bikorimana; Jennifer C Rodriguez; Ema M Khan; Khadeeja Shahid; Sarah J Freemantle; Michael J Spinella Journal: Cancers (Basel) Date: 2019-06-08 Impact factor: 6.639
Authors: Jessica H Hartman; Samuel J Widmayer; Christina M Bergemann; Dillon E King; Katherine S Morton; Riccardo F Romersi; Laura E Jameson; Maxwell C K Leung; Erik C Andersen; Stefan Taubert; Joel N Meyer Journal: J Toxicol Environ Health B Crit Rev Date: 2021-02-22 Impact factor: 8.071
Authors: Andrew Sulaiman; Sarah McGarry; Jason Chambers; Emil Al-Kadi; Alexandra Phan; Li Li; Karan Mediratta; Jim Dimitroulakos; Christina Addison; Xuguang Li; Lisheng Wang Journal: Int J Mol Sci Date: 2020-08-12 Impact factor: 5.923
Authors: Nisreen Wahwah; Debanjan Dhar; Hui Chen; Shunhui Zhuang; Adriano Chan; Darren E Casteel; Hema Kalyanaraman; Renate B Pilz; Gerry R Boss Journal: Sci Rep Date: 2020-11-16 Impact factor: 4.996